BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
|Articles|November 1, 2016
- Pharmaceutical Executive-11-01-2016
- Volume 36
- Issue 11
Pharmaceutical Executive, November 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Executive November 2016 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 10 years ago
Pharm Exec's 2017 Pipeline Reportalmost 10 years ago
Digital Disruption is Coming: Are You Ready?almost 10 years ago
8 Winning Commercial Portfolio Strategiesalmost 10 years ago
Building Market Access Competencies for the Futurealmost 10 years ago
Loss of Exclusivity: Strategies to Maximize Product Valuealmost 10 years ago
Flipping the Generics Map: Apotex's Jeremy Desaialmost 10 years ago
The Pipeline: Pressures from Beyondalmost 10 years ago
Has Gastein Peaked?almost 10 years ago
Country Report: SwitzerlandAdvertisement
Related to this article
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Astellas gains an option on Audax’s IL-12 antibody-cytokine fusion DAX-044, while EVERSANA acquires London-based health economics firm Estima Scientific.
Shionogi’s Dr. Draica on why preventative antivirals matter — and how its HIV and flu prevention heritage shaped XOCOVA’s post-exposure focus.
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Rebuilding Clinical Data Workflows for the AI Era
3
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
4
How Preventative Medications May Impact the Lingering Impact of COVID-19
5